CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.29 HKD | -0.56% |
|
+4.13% | +3.12% |
| Apr. 24 | China Resources Pharmaceutical Group Limited Announces Change of Company Secretary | CI |
| Apr. 18 | China Resources Pharma Unit Issues 3 Billion Yuan Bonds | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 45,437 | 25,004 | 22,303 | 39,705 | 32,229 | 33,234 | - | - |
| Enterprise Value (EV) 1 | 74,178 | 57,928 | 61,337 | 73,426 | 68,431 | 66,192 | 64,928 | 59,779 |
| P/E ratio | 13.9 x | 7.65 x | 5.92 x | 9.58 x | 8.41 x | 7.45 x | 6.58 x | 6.18 x |
| Yield | 1.52% | 3.02% | 4.23% | 2.53% | 3% | 3.11% | 3.49% | 3.68% |
| Capitalization / Revenue | 0.22 x | 0.12 x | 0.09 x | 0.16 x | 0.13 x | 0.12 x | 0.11 x | 0.1 x |
| EV / Revenue | 0.36 x | 0.29 x | 0.26 x | 0.29 x | 0.28 x | 0.24 x | 0.21 x | 0.18 x |
| EV / EBITDA | 5.9 x | 4.91 x | 4.83 x | 4.38 x | 4.82 x | 4.05 x | 3.58 x | 3.06 x |
| EV / FCF | 11.3 x | 8.86 x | 5.88 x | 7.47 x | - | 12.8 x | 9.53 x | 6.62 x |
| FCF Yield | 8.82% | 11.3% | 17% | 13.4% | - | 7.84% | 10.5% | 15.1% |
| Price to Book | 1.12 x | 0.54 x | 0.44 x | 0.8 x | 0.35 x | 0.64 x | 0.57 x | 0.51 x |
| Nbr of stocks (in thousands) | 6,284,506 | 6,282,510 | 6,282,510 | 6,282,510 | 6,282,510 | 6,282,510 | - | - |
| Reference price 2 | 7.230 | 3.980 | 3.550 | 6.320 | 5.130 | 5.290 | 5.290 | 5.290 |
| Announcement Date | 3/30/20 | 3/26/21 | 3/29/22 | 3/30/23 | 3/26/24 | - | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 204,454 | 200,423 | 236,806 | 254,106 | 244,704 | 280,147 | 311,585 | 340,362 |
| EBITDA 1 | 12,576 | 11,790 | 12,690 | 16,775 | 14,191 | 16,327 | 18,143 | 19,562 |
| EBIT 1 | 10,212 | 9,346 | 9,868 | 13,623 | 11,027 | 13,492 | 14,780 | 15,830 |
| Operating Margin | 4.99% | 4.66% | 4.17% | 5.36% | 4.51% | 4.82% | 4.74% | 4.65% |
| Earnings before Tax (EBT) 1 | 6,640 | 7,076 | 8,408 | 9,856 | 9,880 | 11,553 | 12,899 | 14,096 |
| Net income 1 | 3,286 | 3,297 | 3,769 | 4,147 | 3,854 | 4,565 | 5,108 | 5,427 |
| Net margin | 1.61% | 1.65% | 1.59% | 1.63% | 1.58% | 1.63% | 1.64% | 1.59% |
| EPS 2 | 0.5200 | 0.5200 | 0.6000 | 0.6600 | 0.6100 | 0.7104 | 0.8035 | 0.8557 |
| Free Cash Flow 1 | 6,544 | 6,537 | 10,428 | 9,833 | - | 5,191 | 6,817 | 9,035 |
| FCF margin | 3.2% | 3.26% | 4.4% | 3.87% | - | 1.85% | 2.19% | 2.65% |
| FCF Conversion (EBITDA) | 52.04% | 55.45% | 82.17% | 58.62% | - | 31.79% | 37.57% | 46.19% |
| FCF Conversion (Net income) | 199.13% | 198.27% | 276.68% | 237.09% | - | 113.72% | 133.46% | 166.48% |
| Dividend per Share 2 | 0.1100 | 0.1200 | 0.1500 | 0.1600 | 0.1540 | 0.1648 | 0.1845 | 0.1945 |
| Announcement Date | 3/30/20 | 3/26/21 | 3/29/22 | 3/30/23 | 3/26/24 | - | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 102,531 | 89,387 | 111,036 | 114,488 | 122,319 | 125,716 | 128,390 | 138,940 | 105,764 | 143,431 | 128,098 | 159,867 | 143,329 |
| EBITDA | - | - | 4,573 | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | 3,711 | 6,481 | 4,058 | 7,822 | 5,801 | 7,745 | 3,282 | 8,373 | 5,151 | 9,600 | 5,171 |
| Operating Margin | - | - | 3.34% | 5.66% | 3.32% | 6.22% | 4.52% | 5.57% | 3.1% | 5.84% | 4.02% | 6.01% | 3.61% |
| Earnings before Tax (EBT) | - | - | 2,586 | - | - | - | - | 7,117 | 2,763 | - | - | - | - |
| Net income | - | - | 719.9 | - | - | - | - | 3,038 | 816.2 | - | - | - | - |
| Net margin | - | - | 0.65% | - | - | - | - | 2.19% | 0.77% | - | - | - | - |
| EPS 2 | 0.0400 | 0.4100 | 0.1100 | 0.3900 | 0.2100 | 0.4800 | 0.1800 | - | 0.1300 | 0.4800 | 0.2000 | 0.5500 | 0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 8/27/20 | 3/26/21 | 8/25/21 | 3/29/22 | 8/25/22 | 3/30/23 | 8/31/23 | 3/26/24 | - | - | - | - |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 28,741 | 32,924 | 39,035 | 33,720 | 36,202 | 32,957 | 31,693 | 26,545 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.285 x | 2.792 x | 3.076 x | 2.01 x | 2.551 x | 2.019 x | 1.747 x | 1.357 x |
| Free Cash Flow 1 | 6,544 | 6,537 | 10,428 | 9,833 | - | 5,191 | 6,817 | 9,035 |
| ROE (net income / shareholders' equity) | 8.21% | 7.56% | 7.73% | 8.25% | 8.61% | 8.47% | 8.75% | 8.23% |
| ROA (Net income/ Total Assets) | 1.8% | 1.65% | 1.65% | 1.69% | 1.67% | 2.3% | 2.4% | 2.3% |
| Assets 1 | 183,087 | 199,693 | 228,973 | 244,931 | 231,152 | 198,882 | 213,020 | 236,121 |
| Book Value Per Share 2 | 6.480 | 7.400 | 8.110 | 7.890 | 14.80 | 8.220 | 9.300 | 10.30 |
| Cash Flow per Share 2 | 1.910 | 2.140 | 2.040 | 5.140 | - | 2.000 | 1.280 | 1.340 |
| Capex 1 | 1,597 | 1,669 | 2,415 | 2,798 | - | 3,446 | 3,946 | 4,057 |
| Capex / Sales | 0.78% | 0.83% | 1.02% | 1.1% | - | 1.23% | 1.27% | 1.19% |
| Announcement Date | 3/30/20 | 3/26/21 | 3/29/22 | 3/30/23 | 3/26/24 | - | - | - |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.29
HKD
Average target price
7.406
HKD
Spread / Average Target
+39.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.12% | 4.27B | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B |
- Stock Market
- Equities
- 3320 Stock
- Financials China Resources Pharmaceutical Group Limited